<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13653">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380367</url>
  </required_header>
  <id_info>
    <org_study_id>V501-029</org_study_id>
    <secondary_id>2006_038</secondary_id>
    <nct_id>NCT00380367</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)</brief_title>
  <official_title>Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>India: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent HPV
      vaccine in healthy females 9 to 15 years of age in India.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Percentage of Subjects Who Serologically Convert to Each of Human Papilloma Virus (HPV) 6, 11, 16, 18 at Week 4 Postdose 3 (Month 7)</measure>
    <time_frame>7 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Month 7 HPV cLIA seroconversion rates among subjects who received Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) L 1 VLP vaccine (per‐protocol immunogenicity population ).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Injection Site Adverse Experiences (AE), and Any Adverse Experiences (AE) That Occur Throughout the Study</measure>
    <time_frame>7 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Papillomavirus Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V501</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine</intervention_name>
    <description>Quadrivalent HPV vaccine (6,11,16,18) given on day 1, month 2 &amp; month 6, 7 months of treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Females Age 9 To 15 Years

          -  Females Not Sexually Active And Not Plan On Becoming Sexually Active During The Study

          -  No Fevers 24 Hours Prior To The First Injection

        Exclusion Criteria:

          -  Subject Had Received A Prior Vaccination With A HPV Vaccine

          -  Subject Has Allergies To Vaccine Component Including Aluminum And Yeast

          -  Subject Has (Human Immunodeficiency Virus) HIV Infection

          -  Subject Is Immunocompromised

          -  Subject Received Or Plans To Receive Blood-Derived Product Within 6 Months Prior To
             The First Injection

          -  Subject Received Or Plans To Receive Immune Globulin Preparation Within 6 Months To
             The First Injection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 27, 2015</lastchanged_date>
  <firstreceived_date>September 22, 2006</firstreceived_date>
  <firstreceived_results_date>January 22, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase III
First Patient In (FPI): 03 May 2007
Last Patient In (LPI): 04 Feb 2008
Multi-center study. Seven sites participated in the study. All sites were medical centers located in Bangalore, Mumbai and Pune.</recruitment_details>
      <pre_assignment_details>Open-label, single-arm, nonrandomized study. Females &gt; 9 to 15 years of age, who have not had coitarche and did not plan on becoming sexually active through the course of the study, who did not have a feverish feeling within 24 hours prior to the first injection, at first vaccination were included in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)</title>
          <description>Subjects who were enrolled received Quadrivalent Human Papilloma Virus (HPV) VLP (Virus like particles) vaccine (6,11,16,18) given on day 1, month 2 and month 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)</title>
          <description>Subjects who were enrolled received Quadrivalent Human Papilloma Virus (HPV) VLP (Virus like particles) vaccine (6,11,16,18) given on day 1, month 2 and month 6</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="110"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11.54" spread="1.67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="110"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16.76" spread="2.79"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="143.32" spread="9.58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34.90" spread="8.81"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Injection Site Adverse Experiences (AE), and Any Adverse Experiences (AE) That Occur Throughout the Study</title>
        <time_frame>7 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Only the subjects who had safety follow‐up data were included in the safety summaries.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)</title>
            <description>Subjects who were enrolled received Quadrivalent Human Papilloma Virus (HPV) VLP (Virus like particles) vaccine (6,11,16,18) given on day 1, month 2 and month 6</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Injection Site Adverse Experiences (AE), and Any Adverse Experiences (AE) That Occur Throughout the Study</title>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Injection site AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Other AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Serologically Convert to Each of Human Papilloma Virus (HPV) 6, 11, 16, 18 at Week 4 Postdose 3 (Month 7)</title>
        <description>Month 7 HPV cLIA seroconversion rates among subjects who received Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) L 1 VLP vaccine (per‐protocol immunogenicity population ).</description>
        <time_frame>7 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>The number of subjects contributing to the analysis includes all subjects who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant Human Papilloma Virus (HPV) type(s), and had a Month 7 serum sample collected within an acceptable day range.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)</title>
            <description>Subjects who were enrolled received Quadrivalent Human Papilloma Virus (HPV) VLP (Virus like particles) vaccine (6,11,16,18) given on day 1, month 2 and month 6</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects Who Serologically Convert to Each of Human Papilloma Virus (HPV) 6, 11, 16, 18 at Week 4 Postdose 3 (Month 7)</title>
            <description>Month 7 HPV cLIA seroconversion rates among subjects who received Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) L 1 VLP vaccine (per‐protocol immunogenicity population ).</description>
            <units>Percentage of subjects</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV 6 [Number of Participants Analyzed 99]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96.97" lower_limit="93.59" upper_limit="100.35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV 11</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99.05" lower_limit="97.19" upper_limit="100.91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV 16</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99.05" lower_limit="97.19" upper_limit="100.91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99.05" lower_limit="97.19" upper_limit="100.91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)</title>
          <description>Subjects who were enrolled received Quadrivalent Human Papilloma Virus (HPV) VLP (Virus like particles) vaccine (6,11,16,18) given on day 1, month 2 and month 6</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
